Academic trend at home and abroad

Interpretation of global stroke report data in 2025: gradient evolution and precise management of stroke burden

  • TANG Chunhua ,
  • GUO Lu ,
  • ZHANG Lili
Expand
  • Department of Neurology, Army Characteristic Medical Center, Army Medical University, Chongqing 400038, China

Received date: 2025-06-30

  Revised date: 2025-09-03

  Accepted date: 2025-09-11

  Online published: 2025-10-25

Abstract

In 2021, there were 93.816 million prevalent cases of stroke worldwide [age-standardized prevalence rate(ASPR) 1 099/100 000], with 11.946 million new cases in that year [age-standardized incidence rate(ASIR) 142/100 000]. Among these new cases, ischemic stroke (IS), intracerebral hemorrhage (ICH), and subarachnoid hemorrhage (SAH) accounted for 65.3% (7.804 million), 28.8% (3.444 million), and 5.8% (0.697 million), respectively. In the same year, stroke caused 7.253 million deaths, accounting for 10.7% of all global deaths. Deaths caused by IS, ICH, and SAH accounted for 49.5% (3.591 million), 45.6% (3.308 million), and 4.9% (353 000), respectively. In 2021, stroke remained the second leading cause of death worldwide, with its core disease burden indicator — disability-adjusted life years (DALYs) — exceeding 160 million, ranking third among all global total disease burdens. In terms of economic burden, the global direct medical costs and productivity losses caused by stroke reached 890 billion USD in 2021 (accounting for 0.66% of the global GDP), and are projected to exceed 1.8 trillion USD by 2050 if the current growth rate persists. The global stroke burden exhibits a dual trend of "increasing absolute numbers but decreasing age-standardized rates". Low- and middle-income countries bear most of the disease burden, and the incidence of stroke shows a coexistence of younger and older onset. In terms of risk factors, the burden of traditional behavior-related risks has decreased, while the attributable burden of metabolic and climate-related risks is rapidly increasing. China bears the heaviest stroke burden globally, characterized by a “four-high” pattern of “high incidence, high prevalence, medium-to-high mortality, and medium-to-high DALYs”, with significant urban-rural and regional disparities. This condition results from the combined effects of accelerated population aging and continuously increasing exposure to risk factors. In 2021, there were 26.335 million prevalent cases in China, with ASPR of 1 301.4/100 000. In 2021, there were 4.09 million new stroke cases in China (ASIR 204.8/100 000), accounting for 34.2% of all new global cases—far exceeding China's proportion of the world's population (about 20%). IS accounted for 67.8% [2.772 million cases, age-standardized incidence rate (ASIR) 135.8/100 000], and ICH accounted for 28.7% (1.173 million cases, ASIR 61.2/100 000). The annual total economic burden of stroke in China has exceeded 400 billion RMB, with its proportion in the national healthcare expenditure continuing to increase. Direct medical costs account for about 60%, while indirect costs (including productivity losses and caregiving expenses) account for 40%, imposing a dual pressure on both society and families. To address this challenge, a stratified precision prevention and control system centered on the coordination of "policy-healthcare-society" should be established, covering primordial, primary, and secondary prevention levels. Emphasis should be placed on cross-sector collaboration, data-driven approaches, and international experience sharing to achieve effective control of the stroke burden and promote global health equity.

Cite this article

TANG Chunhua , GUO Lu , ZHANG Lili . Interpretation of global stroke report data in 2025: gradient evolution and precise management of stroke burden[J]. Journal of Diagnostics Concepts & Practice, 2025 , 24(05) : 485 -497 . DOI: 10.16150/j.1671-2870.2025.05.003

References

[1] GBD 2021 Stroke Risk Factor Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet Neurol, 2024, 23(10):973-1003.
[2] FEIGIN V L, BRAININ M, NORRVING B, et al. World Stroke Organization: Global Stroke Fact Sheet 2025[J]. Int J Stroke, 2025, 20(2):132-144.
[3] PARRY-JONES A R, KRISHNAMURTHI R, ZIAI W C, et al. World Stroke Organization (WSO): Global intracerebral hemorrhage factsheet 2025[J]. Int J Stroke, 2025, 20(2):145-150.
[4] GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet, 2023, 402(10397):203-234.
[5] FEIGIN V L, OWOLABI M O, World Stroke Organization-Lancet Neurology Commission Stroke Collaboration Group. Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization-Lancet Neurology Commission[J]. Lancet Neurol, 2023, 22(12):1160-1206.
[6] SONG D, XU D, LI M, et al. Global, regional, and national burdens of intracerebral hemorrhage and its risk factors from 1990 to 2021[J]. Eur J Neurol, 2025, 32(1):e70031.
[7] ROMANELLO M, NAPOLI C D, GREEN C, et al. The 2023 report of the Lancet Countdown on health and climate change: the imperative for a health-centred response in a world facing irreversible harms[J]. Lancet, 2023, 402(10419):2346-2394.
[8] LI X, JIN T, BAI C, et al. Analysis of Stroke Burden in China from 1990 to 2021 and Projections for the Next Decade[J]. Neuroepidemiology, 2024.
[9] 翟屹, 杨帆, 李天琪, 等. 中国卒中疾病负担与经济负担的整合分析[J]. 中国卒中杂志, 2025, 20(5):566-580.
  ZHAI Y, YANG F, LI T Q, et al. An integrated analysis of disease burden and economic burden of stroke in China[J]. Chin J Stroke, 2025, 20(5):566-580.
[10] 中国高血压防治指南修订委员会, 高血压联盟(中国), 中国医疗保健国际交流促进会高血压分会, 等. 中国高血压防治指南(2024年修订版)[J]. 中华高血压杂志, 2024, 32(7):603-700.
  China Hypertension Prevention and Treatment Guideline Revision Committee, Hypertension Alliance (China), Hypertension Branch of China Association for the Promotion of International Exchanges in Healthcare, et al. Chinese guidelines for the prevention and treatment of hypertension (revised in 2024)[J]. Chin J Hypertens, 2024, 32(7):603-700.
[11] JIA W, CHAN J C, WONG T Y, et al. Diabetes in China: epidemiology, pathophysiology and multi-omics[J]. Nat Metab, 2025, 7(1):16-34.
[12] ZENG X, LIU S, LIU Y, et al. Smoking prevalence in Urban and Rural Areas - China, 2024[J]. China CDC Wkly, 2025, 7(22):751-759.
[13] 国家心血管病中心, 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2024概要[J]. 中国循环杂志, 2025, 40(6):521-559.
  National Center for Cardiovascular Diseases, The Writing Committee of the Report on Cardiovascular Health and Diseases in China. Report on cardiovascular health and diseases in China 2024: an updated summary[J]. Chin Circ J, 2025, 40(6):521-559.
[14] GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affec-ting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet Neurol, 2024, 23(4):344-381.
[15] 《中国卒中中心报告2022》编写组. 《中国卒中中心报告2022》概要[J]. 中国脑血管病杂志, 2024, 21(8):565-576.
  Report on Stroke Center in China Writing Group. Brief report on stroke center in China,2022[J]. Chin J Cerebrovasc, 2024, 21(8):565-576.
[16] 中国营养学会中国居民膳食指南科学报告工作组. 《中国居民膳食指南科学研究报告(2021)》简本[J]. 营养学报, 2021, 43(2):102.
  Working Group of Scientific Report on Dietary Guidelines for Chinese Residents of Chinese Nutrition Society. Abridged edition of Scientific Research Report on dietary guidelines for Chinese residents (2021)[J]. Acta Nutrimenta Sin, 2021, 43(2):102.
[17] TU W J, ZHAO Z, YIN P, et al. Estimated burden of stroke in China in 2020[J]. JAMA Netw Open, 2023, 6(3):e231455.
[18] The Lancet Neurology. Tackling the burden of stroke with primordial prevention[J]. Lancet Neurol, 2022, 21(12):1061.
[19] KOEN N, EBRAHIM Z, LOUISA MARAIS M, et al. Taxation of sugar-sweetened beverages in South Africa: Perspectives of consumers in Cape Town[J]. J Public Health Res, 2022, 11(4):22799036221129369.
[20] ROGERS N T, CUMMINS S, JONES C P, et al. Estimated changes in free sugar consumption one year after the UK soft drinks industry levy came into force: controlled interrupted time series analysis of the National Diet and Nutrition Survey (2011-2019)[J]. J Epidemiol Community Health, 2024, 78(9):578-584.
[21] MITTAL L, BAKER T, Environmental Research Group, Imperial College London. London Air Quality Network - summary report 2022[R/OL]. 2022. https://www.londonair.org.uk/london/reports/2022_LAQN_Report.pdf.
[22] WHYTE M, DOUWES J, RANTA A. Green space and stroke: A scoping review of the evidence[J]. J Neurol Sci, 2024, 457:122870.
[23] AGANA D F G, SALEMI J L, STRILEY C W. From primary care to the revolving door of hospital readmission: Relevance of Geoffrey Rose's call for a population strategy[J]. Prev Med Rep, 2019, 14:100848.
[24] STEVENSON M, THOMPSON J, DE Sá T H, et al. Land use, transport, and population health: estimating the health benefits of compact cities[J]. Lancet, 2016, 388(10062):2925-2935.
[25] HE F J, BRINSDEN H C, MACGREGOR G A. Salt reduction in the United Kingdom: a successful experiment in public health[J]. J Hum Hypertens, 2014, 28(6):345-352.
[26] BRINDLE P M, MCCONNACHIE A, UPTON M N, et al. The accuracy of the Framingham risk-score in different socioeconomic groups: a prospective study[J]. Br J Gen Pract, 2005, 55(520):838-845.
[27] ZHAO J, LI X, LIU X, et al. Changing the strategy and culture of stroke awareness education in China: implementing Stroke 1-2-0[J]. Stroke Vasc Neurol, 2020, 5(4):374-380.
[28] FEIGIN V L, KRISHNAMURTHI R, BHATTACHARJEE R, et al. New strategy to reduce the global burden of stroke[J]. Stroke, 2015, 46(6):1740-1747.
[29] CHANG A Y, RAHMAN M, TALUKDER A, et al. Effectiveness of a community health worker-led low-sodium salt intervention to reduce blood pressure in rural Bangladesh: protocol for a cluster randomized controlled trial[J]. Trials, 2023, 24(1):480.
[30] WANG W Z, JIANG B, WU S P, et al. Change in stroke incidence from a population-based intervention trial in three urban communities in China[J]. Neuroepidemiology, 2007, 28(3):155-161.
[31] VERBURGT E, HILKENS N A, EKKER M S, et al. Short-term and long-term risk of recurrent vascular event by cause after ischemic stroke in young adults[J]. JAMA Netw Open, 2024, 7(2):e240054.
[32] BILLINGER S A, ARENA R, BERNHARDT J, et al. Physical activity and exercise recommendations for stroke survivors: a statement for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2014, 45(8):2532-2553.
[33] 国家卫健委脑卒中防治工程委员会专家委员会, 中华医学会急诊分会, 中国卒中学会急救医学分会, 等. 中国5G移动卒中单元院前诊疗管理指南[J]. 中华神经医学杂志, 2023, 22(1):2-17.
  Expert Committee of Stroke Prevention and Treatment Engineering Committee of National Health Commission, Emergency Branch of Chinese Medical Association, Emergency Medicine Branch of Chinese Stroke Society, et al. Guidelines on 5G mobile stroke unit for prehospital diagnosis and management in China[J]. Chin J Neuromed, 2023, 22(1):2-17.
[34] NOGUEIRA R G, JADHAV A P, HAUSSEN D C, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct[J]. N Engl J Med, 2018, 378(1):11-21.
[35] ALBERS G W, MARKS M P, KEMP S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging[J]. N Engl J Med, 2018, 378(8):708-718.
[36] LAPERGUE B, BLANC R, GORY B, et al. Effect of endovascular contact aspiration vs stent retriever on revascularization in patients with acute ischemic stroke and large vessel occlusion: The ASTER Randomized Clinical Trial[J]. JAMA, 2017, 318(5):443-452.
[37] TAN J, GONG E, GALLIS J A, et al. Primary care-based digital health-enabled stroke management intervention: Long-term follow-up of a cluster randomized clinical trial[J]. JAMA Netw Open, 2024, 7(12):e2449561.
[38] CHOI Y Y C, FINEBERG M, KASSAVOU A. Effectiveness of remote interventions to improve medication adhe-rence in patients after stroke: A systematic literature review and meta-analysis[J]. Behav Sci (Basel), 2023, 13(3):246.
[39] GAO L, CHURILOV L, JOHNS H, et al. Cost-effectiveness of endovascular thrombectomy in patients with large ischemic stroke[J]. Ann Neurol, 2025, 97(2):222-231.
[40] MACINKO J, SEIXAS B V, DE OLIVEIRA C, et al. Private health insurance, healthcare spending and utilization among older adults: Results from the Brazilian Longitudinal Study of Aging[J]. J Econ Aging, 2022, 23:100397.
[41] 唐春花, 张莉莉. 急性缺血性卒中急性期药物治疗进展[J]. 重庆医科大学学报, 2024, 49(5):508-514.
  TANG C H, ZHANG L L. Advances in pharmacotherapy for the acute stage of acute ischemic stroke[J]. J Chong-qing Med Univ, 2024, 49(5):508-514.
[42] 党翠娇, 刘贵先, 潘卫东. 脑白质病变危险因素分析及其与脑卒中和痴呆的相关性研究[J]. 神经病学与神经康复学杂志, 2024, 20(3):85-91.
  DANG C J, LIU G X, PAN W D. Analysis of risk factors for white matter lesion and its correlation with stroke and dementia[J]. J Neurol Neurorehabil, 2024, 20(3):85-91.
[43] 李淑晓, 李兴超, 王友芳, 等. 血浆致动脉硬化指数对不同年龄急性缺血性脑卒中血管内介入治疗短期预后的评估[J]. 中国临床研究, 2024, 37(8):1234-1237,1243.
  LI S Y, LI X C, WANG Y F, et al. Evaluation of plasma atherogenic index on short-term prognosis of intravascular interventional therapy in patients with acute ischemic stroke[J]. Chin J Clin Res, 2024, 37(8):1234-1237,1243.
Outlines

/